Book contents
- Frontmatter
- Contents
- Preface
- Introduction
- Acetazolamide
- ACTH
- Carbamazepine
- Clobazam
- Clonazepam
- Diazepam
- Eslicarbazepine acetate
- Ethosuximide
- Felbamate
- Fosphenytoin
- Gabapentin
- Lacosamide
- Lamotrigine
- Levetiracetam
- Lorazepam
- Methsuximide
- Midazolam
- Oxcarbazepine
- Paraldehyde
- Phenobarbital
- Phenytoin
- Piracetam
- Pregabalin
- Primidone
- Rufinamide
- Stiripentol
- Sulthiame
- Tiagabine
- Topiramate
- Valproate
- Vigabatrin
- Zonisamide
- Abbreviations
- Interaction Table
- Index
Introduction
Published online by Cambridge University Press: 04 August 2010
- Frontmatter
- Contents
- Preface
- Introduction
- Acetazolamide
- ACTH
- Carbamazepine
- Clobazam
- Clonazepam
- Diazepam
- Eslicarbazepine acetate
- Ethosuximide
- Felbamate
- Fosphenytoin
- Gabapentin
- Lacosamide
- Lamotrigine
- Levetiracetam
- Lorazepam
- Methsuximide
- Midazolam
- Oxcarbazepine
- Paraldehyde
- Phenobarbital
- Phenytoin
- Piracetam
- Pregabalin
- Primidone
- Rufinamide
- Stiripentol
- Sulthiame
- Tiagabine
- Topiramate
- Valproate
- Vigabatrin
- Zonisamide
- Abbreviations
- Interaction Table
- Index
Summary
The purpose of The Epilepsy Prescriber's Guide to Antiepileptic Drugs (AEDs) is to provide practical and concise information so as to allow the optimum use of AEDs in clinical practice. This quick reference guide provides a wealth of invaluable information for use by all who treat patients with epilepsy, including neurologists, neurosurgeons, general physicians, those caring for the elderly, emergency medicine doctors, medical students and trainees at all levels, general practitioners, nurses and epilepsy nurse specialists, and practice pharmacists.
All of the drugs are presented in the same design format and in alphabetical order to facilitate rapid access to information. Specifi cally, each drug is divided into eight sections and each section is designated by a unique color background: therapeutics, pharmacokinetics, drug interaction profi le, adverse eff ects, dosing and use, special populations, and the overall place of the drug in the treatment of epilepsy, followed by suggested reading of key references.
Section 1: Therapeutics
Covers the chemical name and structure; brand names in major countries; generics available; licensed indications as approved by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) or the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA); nonlicensed use; seizure types for which the drug is ineff ective or contraindicated; mechanism of action; effi cacy profile.
- Type
- Chapter
- Information
- Publisher: Cambridge University PressPrint publication year: 2010